Clarithromycin is an antibiotic that is used to treat many different types of bacterial infections affecting the skin and respiratory system
Biaxin XL is used to treat many different types of bacterial infections affecting the skin and respiratory system
It is available as a capsule, chewable, and liquid
Clarithromycin is known as a macrolide antibiotic
For oral
Generic Name (S): clarithromycin Uses Clarithromycin is used to treat a wide variety of bacterial infections
Official answer by Drugs
Find out how clarithromycin treats chest infections and pneumonia, and how to take it
Find out how clarithromycin treats chest infections and pneumonia, and how to take it
You may need stronger antibiotics if you have certain medical conditions such as heart disease, chronic obstructive pulmonary disease (COPD), diabetes, or
Your doctor will select the most appropriate antibiotic based on your infection and other medical conditions, the patterns of local antibiotic resistance, cost, and other patient-specific characteristics such as your age, weight, allergies, and previous
Bronchiectasis is a persistent or progressive condition caused by chronic inflammatory damage to the airways and is characterised by thick-walled, dilated bronchi
Confusion or changes in mental awareness (in adults age 65 and older) Cough, which may produce phlegm
223
The Cochrane report mentioned above found that patients given antibiotics were more likely to have side effects from them
The disorders treated by azithromycin are important causes of infectious disease morbidity and mortality in the
Clarithromycin is a prescription drug used to treat a wide variety of bacterial infections
Adult Dosage: 250 mg orally every 12 Clarithromycin is used to treat a wide variety of bacterial infections
pyogenes) and gram-negative aerobic bacteria (Haemophilus influenzae, H
3 reviews submitted with a 7
7) After 12 days of therapy, all three clarithromycin treatment regimens had significantly lower BAL cultures compared with placebo we found that elevating the dosage of clarithromycin used to treat experimental M
pneumoniae, recent evidence defining the mechanism of this resistance, coupled with the pharmacokinetic properties of the macrolide agents, suggests that the actual rate Addition of clarithromycin to standard of care enhances early clinical response and attenuates the inflammatory burden of community-acquired pneumonia